Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.

Cell-free protein synthesis (CFPS) systems allow rapid protein production in vitro without the need for living cells, offering distinct advantages.

The European Court of Justice ruling from 2018 which put the latest breeding methods under the EU GMO legislation was a huge pushback for plant breeding innovation in the EU. With the proposal for a new regulation for certain new genomic techniques (NGTs) published on 5 July 2023, some faith in a rebirth of plant breeding innovation may just start to return.

Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.

Scientists led by Heiko Rischer from the Finnish research centre VTT have published the proof of concept for cell-based coffee production.

This scrappy young city in the heart of Europe is rapidly becoming a magnet for successful start-ups and companies looking for plenty of room to grow, as well as a culture of cooperation and trust.

At the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the adapted version of the EU Commission’s draft regulation on new genomic techniques.

Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.
 

On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.

Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.